A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer

Abstract Background Hyperglycemia is an on-target effect of PI3Kα inhibitors. Early identification and intervention of treatment-induced hyperglycemia is important for improving management of patients receiving a PI3Kα inhibitor like alpelisib. Here, we characterize incidence of grade 3/4 alpelisib-...

Full description

Bibliographic Details
Main Authors: Jordi Rodón, David Demanse, Hope S. Rugo, Howard A. Burris, Rafael Simó, Azeez Farooki, Melissa F. Wellons, Fabrice André, Huilin Hu, Dragica Vuina, Cornelia Quadt, Dejan Juric
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Breast Cancer Research
Subjects:
Alpelisib
Hyperglycemia
Machine learning
SOLAR-1
BYLieve
HR+/HER2− advanced breast cancer
Online Access:https://doi.org/10.1186/s13058-024-01773-1

Internet

https://doi.org/10.1186/s13058-024-01773-1

Similar Items